DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 115 filers reported holding DENALI THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $22,703 | -42.1% | 450 | -10.0% | 0.00% | -50.0% |
| Q2 2021 | $39,220 | +37.4% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $28,550 | -31.8% | 500 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $41,880 | +133.8% | 500 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $17,915 | +48.2% | 500 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $12,090 | +38.1% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $8,755 | +0.5% | 500 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $8,710 | +13.7% | 500 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $7,660 | -48.4% | 500 | -30.1% | 0.00% | 0.0% |
| Q2 2019 | $14,843 | -10.6% | 715 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $16,602 | +703.6% | 715 | +615.0% | 0.00% | – |
| Q4 2018 | $2,066 | -5.0% | 100 | 0.0% | 0.00% | – |
| Q3 2018 | $2,174 | +42.6% | 100 | 0.0% | 0.00% | – |
| Q2 2018 | $1,525 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $404,042,000 | 54.41% |
| Bratton Capital Management, L.P. | 953,035 | $19,785,000 | 29.05% |
| Flagship Pioneering Inc. | 8,005,747 | $166,199,000 | 7.19% |
| Casdin Capital, LLC | 400,000 | $8,304,000,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $91,561,000 | 0.65% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,595 | $469,000 | 0.37% |
| MARK ASSET MANAGEMENT LP | 70,532 | $1,464,000 | 0.34% |
| Artal Group S.A. | 400,000 | $8,304,000 | 0.34% |
| PIER 88 INVESTMENT PARTNERS LLC | 27,650 | $574,000 | 0.24% |
| WASATCH ADVISORS LP | 996,147 | $20,680,000 | 0.20% |